Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.15: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 14%; Elevated put/call ratio: 1.46; Below-average business quality.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle diseases, with lead candidate sevasemten in late-stage trials for Duchenne and Becker muscular dystrophies. No products approved and no revenue to date;... Read more
Sell if holding. Engine safety override at $35.15: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 14%; Elevated put/call ratio: 1.46; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Edgewise Therapeutics, Inc.
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45 — benzinga Jun 2, 2026 positive
- NEWS RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48 — benzinga Jun 2, 2026 positive
- NEWS Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52 — benzinga Jun 2, 2026 positive
- NEWS Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today — benzinga Jun 1, 2026 positive
- NEWS Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Miles — benzinga Jun 1, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinesevasemten and EDG-750010-K Item 1A: 'We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.15: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 14%; Elevated put/call ratio: 1.46; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $32.68. Score 4.8/10, moderate confidence.
Take-profit target: $40.09 (+14.1% upside). Prior stop was $32.68. Stop-loss: $32.68.
Concentration risk — Pipeline: sevasemten and EDG-7500; Quality below floor (1.5 < 4.0).
Edgewise Therapeutics, Inc. trades at a P/E of N/A (forward -15.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
18 analysts cover EWTX with a consensus score of 4.2/5. Average price target: $46.
What does Edgewise Therapeutics, Inc. do?Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle...
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle diseases, with lead candidate sevasemten in late-stage trials for Duchenne and Becker muscular dystrophies. No products approved and no revenue to date; $530.1M cash as of Dec 31, 2025.